Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases.

The Company's lead therapeutic compound, MBX-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). MBX-400 has successfully completed Phase 1 clinical testing.

The Company is also developing a type III secretion (T3SS) inhibitor for use against multidrug-resistant Pseudomonas aeruginosa infections, a WHO Priority 1 pathogen.